MSACL 2024 : Van Eyk

MSACL 2024 Industry Workshop Presentation

*This Podium Presentation is occuring in the context of an Industry Workshop that starts at the time below. Its actual start time may be up to 40 minutes later, depending on order of presentation if there are multiple presentations planned by the workshop host.

Workshop Host:Thermo Fisher Scientific
Day:Thursday March 21
Location:Steinbeck 1 (Conference Ctr > 2nd Floor)

Paradigm shift in biomarker translation: an innovative and automated pipeline to generate and select clinical-grade signature peptides during DIA discovery
Jennifer Van Eyk, PhD
Cedars-Sinai Heart Institute

Presenter Bio: Jennifer Van Eyk, PhD, is an international leader in the area of clinical proteomics and her lab has focused on developing technical pipelines for de novo discovery and larger scale quantitative mass spectrometry methods. This includes multiple reaction monitoring (MRM, also known as SRM) and most recently data independent acquisition. Dr. Van Eyk's laboratory is well known for the extreme technical quality of the data generated, rigorous quality control with tight %CV while applying these to key clinical questions. The aim is to maximize throughput and reproducibility in order to move targeted and robust discovery methods into large population healthy continuous assessment and clinical grade assays focusing on brain and cardiovascular diseases.


In combination with clinical data and computational analysis, large-cohort proteomics study brings opportunities in improving early diagnosis, refining patient stratification, and predicting/monitoring treatment response. Yet, to achieve meaningful biological insights in large-cohort studies, robust, reproducible, and comprehensive proteome profiling in a high-throughput manner still remains challenging.

Speakers will discuss the performance of the novel Thermo Scientific™ Orbitrap™ Astral™ mass spectrometer for plasma proteomics using the most common plasma sample preparation methods (neat plasma, depleted plasma, and enriched plasma). The Orbitrap Astral MS enables twice the proteome coverage compared to the current commercial mass spectrometers for the same gradient. In addition, with double the throughput, it provides higher proteome coverage. With a throughput of 100 samples/day, we can reproducibly profile ~9000 proteins from human cell line and ~800 proteins from undepleted plasma across multiple instruments and more than 10 consecutive days in a 24/7 operation mode. These results demonstrate this Orbitrap Astral mass platform can comprehensively analyze the proteome of >1000s of sample robustly and reproducibly in a high-throughput manner, addressing the needs in large-cohort studies.